Analyzing Trevena (NASDAQ:TRVN) and Ampio Pharmaceuticals (NYSE:AMPE)

Earnings & Valuation

This table compares Ampio Pharmaceuticals and Trevena”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
Trevena	$443,000.00	0.00	-$40.29 million	($47.04)	0.00

Ampio Pharmaceuticals has higher earnings, but lower revenue than Trevena. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ampio Pharmaceuticals and Trevena’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

Risk and Volatility

Ampio Pharmaceuticals has a beta of 5.57, indicating that its share price is 457% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.